Donanemab
Down Syndrome (DS)
Michael Rafii, MD, PhDmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
34 Active assets in the Down Syndrome (DS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS National Cancer Institute (NCI) | Phase 3 | BB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BB |
METHOTREXATE National Cancer Institute (NCI) | Phase 3 | BB |
Cytosin-Arabinosid Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
View all 36 →
Same molecule, other indications
Donanemab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →